¹ÙÅ©¶ô½ºÅ©¸²(¾Æ½ÃŬ·Î¹ö) 5g Vacrax Cream 5g
ÀϹÝÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
Èò»öÀÇ Å©¸²Á¦
Á¦Á¶È¸»ç
(ÁÖ)¿¡ÀÌÇÁ·ÎÁ¨¹ÙÀÌ¿À·ÎÁ÷½º
ÆÇ¸Åȸ»ç
(ÁÖ)¿¡ÀÌÇÁ·ÎÁ¨¹ÙÀÌ¿À·ÎÁ÷½º
Çã°¡Á¤º¸
Á¤»ó
(1998.03.11)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ (Antivirals : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
269[±âŸÀÇ ¿ÜÇÇ¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
645204281 \0 ¿ø/5g/°³(2018.03.01) (ÇöÀç¾à°¡) \3,019 ¿ø/5g/°³(2018.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Aciclovir / D06BB03
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
°æÁúÀ¯µ¿ÆÄ¶óÇÉ ,
³ó±Û¸®¼¼¸° ,
µð¸ÞƼÄÜ ,
¹é³³ ,
¹é»ö¹Ù¼¿¸° ,
¼¼Åº¿Ã ,
¼Ò¸£ºñź½ºÅ׾Ʒ¹ÀÌÆ® ,
½ºÅ׾Ƹ±¾ËÄÚ¿Ã ,
Á¤Á¦¼ö ,
ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿ ,
ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ ,
Æú¸®¼Ò¸£º£ÀÌÆ®80
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
645204281
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/5g/°³(2018.03.01) (ÇöÀç¾à°¡)
\3,019 ¿ø/5g/°³(2018.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
Èò»öÀÇ Å©¸²Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ]
ÁÖ¼ººÐÄÚµå
102935CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´Ü¼øÆ÷Áø(¹°Áý) ¹ÙÀÌ·¯½º °¨¿°Áõ(ÃÊ±â ¹× Àç¹ß¼º »ý½Ä±â Æ÷Áø(¹°Áý)°ú ±¸¼øÆ÷Áø(ÀÔ¼ú¹°Áý) Æ÷ÇÔ)
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1) ÀÌ ¾àÀº ¾à 4½Ã°£ °£°ÝÀ¸·Î 1ÀÏ 5ȸ ȯºÎ¿¡ ¹Ù¸¥´Ù.
2) Ä¡·á´Â 5Àϰ£ °è¼ÓÇÏ¿©¾ß Çϸç, 5Àϰ£ »ç¿ë ÈÄ¿¡µµ Ä¡·áµÇÁö ¾ÊÀ» °æ¿ì¿¡´Â 5Àϰ£ ´õ »ç¿ëÇÒ ¼ö ÀÖ´Ù.
±Ý±â
1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àְųª ÈÇÐÀû ºÒ³»¼º ȯÀÚ
2) ¼öÀ¯ºÎ
3) ¼Ò¾Æ
½ÅÁßÅõ¿©
1) ¿¡ÀÌÁî ȯÀÚ ¶Ç´Â °ñ¼ö(»À¼ÓÁú)ÀÌ½Ä È¯ÀÚ µî ¸é¿ª°áÇÌ È¯ÀÚ
2) ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.(ÇÔÀ¯Á¦Ç°¿¡ ÇÑÇÔ)
ÀÌ»ó¹ÝÀÀ
1) ±Ë¾çÀÌ »ý±ä »ý½Ä±â ºÎÀ§ÀÇ Æ¯¼º»ó ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ¾ÐÅë µîÀÇ ºÒÄè°¨À» ´À³¥ ¼ö ÀÖ´Ù.
2) ÀϽÃÀûÀÎ ÀÛ¿°¨, ÀÚÅëÀ» Æ÷ÇÔÇÏ´Â °¡º¿î µ¿Åë ¹× Á¢ÃËÇǺο°, È«¹Ý¼º ¹ßÁø, ½ÀÁø, ¾Ë·¹¸£±â¹ÝÀÀ ¹× ¶§¶§·Î µµÆ÷ºÎÀ§ÀÇ Àڱذ¨, °¡·Á¿ò, ¿ÜÀ½¿°, ¾È¸é ºÎÁ¾, ÇǺΠŻ»ö, µÎµå·¯ ±â, ¹ßÁø, ¼Ò¼öÆ÷¼º ¹ßÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) È«¹Ý, °¡·Á¿òÀÌ ³ªÅ¸³ª°Å³ª ÇǺΰ¡ ¾à°£ °ÇÁ¶ÇØÁö°í ¹þ°ÜÁú ¼ö ÀÖ´Ù.
»óÈ£ÀÛ¿ë
ÀÌ ¾à°ú ¿¬°ü¼ºÀº ¹àÇôÁöÁö ¾Ê¾ÒÀ¸³ª, Àü½ÅÅõ¿©ÇÑ ¾Æ½ÃŬ·Î¹öÀÇ Ç÷Àå ¹Ý°¨±â ¹× AUC°¡ ÇÁ·Îº£³×½Ãµå¿¡ ÀÇÇØ Áõ°¡ÇÏ¿´´Ù.
Off-label Usage
[Á¶È¸]
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
645204281
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/5g/°³(2018.03.01) (Ãֽžడ)
\3,019 ¿ø/5g/°³(2018.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
Á¦Ç°¼º»ó
Èò»öÀÇ Å©¸²Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
º¸°ü¹æ¹ý
±â¹Ð¿ë±â, ½Ç¿Â(1~30¡É)º¸°ü
Brandname Á¤º¸
Acyclovir Brand Names/Synonyms
AC2
Aciclovier
Aciclovir
Acycloguanosine
Acyclovir Sodium
Alti-Acyclovir
Avirax
Valtrex
Vipral
Virorax
Wellcome-248u
Zovirax
Zovirax Wellstat Pac
Zovirax Zostab Pac Brand Name Mixtures Zovirax Injection (Zovirax sodium)Chemical IUPAC Name 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Bµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[Å©¸²]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-29
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields:
The generic name of each chemical
For module A10 (liver enzyme composite module):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method)
Number of endpoints at which each compound is marginally active (M)
Number of endpoints at which each compound is active (A)
For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively):
Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method)
Number of ADR reports for each compound, given as <4 or ¡Ã4
Reporting Index value for each compound, except where no shipping units were available (NSU)
Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period.
ACYCLOVIR [GGT Increase] [Composite Activity] (Score) I (Marginal) 0 (Active) 0 [Alkaline Phosphatase Increase] (Activity Score) I (Number of Rpts) ¡Ã4 (Index value) 0.9 [SGOT Increase] (Activity Score) I (Number of Rpts) ¡Ã4 (Index value) 0.9 [SGPT Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0.1 [LDH Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0.1 [GGT Increase] (Activity Score) I (Number of Rpts) <4 (Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ